Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

40.57 -0.03 (-0.07%)
Official Closing Price Updated: 7:00 PM EDT, Aug 5, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,820,918
Open 40.09
Bid (Size) 40.20 (2)
Ask (Size) 43.00 (5)
Prev. Close 40.60
Today's Range 40.07 - 40.63
52wk Range 37.80 - 46.97
Shares Outstanding 5,385,189,617
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Biotech Investors: August's Key PDUFA Catalysts You Must Know
Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the... 
Via Benzinga
Recap Of Friday's Biotech Catalysts - End of The Day Summary
 
Via Benzinga

Performance

YTD
-7.10%
-7.10%
1 Month
-4.18%
-4.18%
3 Month
-6.00%
-6.00%
6 Month
-9.82%
-9.82%
1 Year
-0.02%
-0.02%

More News

Read More
Stock Market Rally Powers Higher On Fed Rate Hints; Apple, Microsoft, Meta, Amazon, Google Key Earnings: Weekly Review
Via Investor's Business Daily
Drug Behemoth GSK Delivers Strong Beat And Raise, But Shares Fell
Via Investor's Business Daily
New GSK Q2 Highlights: Shingles Vaccine Back In Demand, Antibiotics Recover, Forecast Boost
Via Benzinga
Codexis Shares Slide On CEO Transition
Via Benzinga
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate
Via Benzinga
Recap of Wednesday's Biotech Catalysts - End of The Day Summary
Via Benzinga
GSK Announces US FDA Approval of Benlysta (Belimumab) for Pediatric Patients With Active Lupus Nephritis
From GSK plc
Via Business Wire
GSK Completes Spin Off Of Its Consumer Healthcare Business
Via Benzinga
IDEAYA's Cancer Candidate Shows Early Tumor Modulation
Via Benzinga
The 3 Best Market Sectors for the Second Half of 2022
Via InvestorPlace
Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy
Via Benzinga
Jim Cramer Says This Stock Costs About $3, But 'If You Wait Long Enough' You Can Buy It For $2
Via Benzinga
Benzinga Before The Bell: Twitter Shareholder Proposal Date Set, T-Mobile's Strong FY22 Outlook, Shopify's Job Cuts And Other Top Financial Stories Wednesday, July 27
Via Benzinga
7 Dividend Stocks to Buy on the Dip
Via InvestorPlace
This Analyst Says GSK Spin-Off Haleon Offers "Best Of Both Consumer Worlds"
Via Benzinga
3 Biotech Stocks to Buy on the Dip
Via InvestorPlace
Benzinga Before The Bell: Musk's Twitter Lawsuit, Uber Penalized For Overcharging People With Disabilities, Johnson & Johnson Cuts Outlook And Other Top Financial Stories Tuesday, July 19
Via Benzinga
Post Mega London Stock Exchange Listing, GSK Spinoff Haleon's Plunge Brings Valuation Concerns To The Fore
Via Benzinga
Air Pollution is a Global Heart and Lung Health Concern
Via FinancialNewsMedia
Topics Climate Change Emissions Energy
Exposures Climate Fossil Fuels
Benzinga Before The Bell: Amazon Wages Price War On Tesco, Biden's Campaign Promise To Free Cannabis Prisoners, H&M Exits Russia And Other Top Financial Stories Monday, July 18
Via Benzinga
The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures
Via Benzinga
Theravance Biopharma, Innoviva Gain On Selling TRELEGY ELLIPTA Royalty Interests
Via Benzinga
Science Wednesday: Where To See Comet K2 As It Passes The Earth
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.